Biomarkers for early detection of high risk cancers: from gliomas to nasopharyngeal carcinoma.
Nasopharyngeal carcinoma (NpC) is a malignant disease associated with Epstein-Barr virus infection, and often diagnosed at an advanced stage. This significantly curtails patient survival. We hypothesize that a panel of biomarkers can be assembled to assess NpC incidence, early detection, and tumor progression during therapeutic intervention. Our thesis rests on a model of successfully predicting high-risk gliomas by means of a carefully crafted panel of molecular mitotic biomarkers (i.e., securin, survivin and MCM2). The strategy we propose holds strong promise for prevention and cure of NpC. The approach we propose seeks to identify certain biomarkers from viral materials, patient tissues and assessment of related diseases, whose signatures, taken together, will be endowed with some degree of congruency, or sense of a coordinated language (i.e., "votes"). Biomarker "voting" will then permit to outline a broad coordinated molecular map for the molecular and epigenetic characterization of each individual patient's NpC tumor. We will draw on the process of contrasting biomarkers in health and disease, which rests on the auto-proteomic concept particularly relevant in high-risk cancer individuals, such as is the case for NpC. In brief we defend, current advances in human proteome profiling proffers the possibility of having individual baseline proteomic profiles using local body fluids (e.g., saliva, nasal secretions, sputum) or systemic fluids (e.g., plasma, serum, cerebrospinal fluid) to unravel a personalized molecular map for high-risk NpC individuals. Regular check-up will monitor for new or impending manifestations of NpC, and provide a secure assessment of incidence and early detection.
Oluwadara
Oluwadayo
O
Division of Oral Biology and Medicine, UCLA School of Dentistry, Los Angeles, CA 90095, USA.
Chiappelli
Francesco
F
Clin Chem. 2002 Aug;48(8):1296-304
12142387
JAMA. 2008 Sep 24;300(12):1417-22
18812532
J Virol. 2000 Nov;74(21):10223-8
11024153
Bioinformation. 2006 Dec 29;1(8):331-4
17597915
Cancer Res. 2004 Sep 15;64(18):6503-10
15374961
J Am Dent Assoc. 2006 Mar;137(3):313-21
16570464
Epidemiol Rev. 1993;15(2):466-85
8174667
Cancer. 1980 Nov 1;46(9):2100-6
6253051
EMBO J. 1998 Mar 16;17(6):1700-9
9501091
Nat Rev Cancer. 2004 Oct;4(10):757-68
15510157
Science. 2003 Mar 14;299(5613):1679-80
12637728
Cell. 1995 Feb 10;80(3):389-99
7859281
Int J Cancer. 2003 Mar 1;103(6):745-51
12516093
Eur J Hum Genet. 2005 Feb;13(2):248-52
15483644
J Virol. 1990 May;64(5):2309-18
2157887
Cancer Prev Res (Phila). 2008 Jun;1(1):12-4
19138931
Nature. 2008 Apr 3;452(7187):571-9
18385731
Clin Otolaryngol Allied Sci. 2001 Apr;26(2):82-92
11309046
Comp Funct Genomics. 2007;:57513
18288251
Hum Pathol. 1990 Aug;21(8):805-10
2167287
Cell Mol Life Sci. 2008 Apr;65(7-8):1007-12
18213447
Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1765-77
17035381
Int J Cancer. 1990 Jun 15;45(6):1033-9
2351484
Semin Cancer Biol. 2002 Dec;12(6):431-41
12450729
Bioinformation. 2008;3(1):47-52
19052666
Science. 1997 Nov 7;278(5340):1054-9
9353179
Semin Cancer Biol. 2001 Dec;11(6):461-7
11669608
J Virol. 2000 Nov;74(22):10681-9
11044112
Science. 1999 Oct 15;286(5439):531-7
10521349
EMBO J. 1997 Oct 15;16(20):6131-40
9359753
J Immunol. 2000 Sep 15;165(6):2975-81
10975805
Int J Cancer. 2000 Feb 1;85(3):358-63
10652427
Oncogene. 2002 Aug 12;21(35):5450-61
12154407
J Natl Cancer Inst. 1990 Feb 21;82(4):291-6
2299678